Likewise, the study by Messenheimer and colleagues showed in a mouse model of breast cancer that while the concurrent anti-PD-1 injection reduced the antitumor effect of anti-OX40 alone, the delayed administration of anti-PD-1 to anti-OX40 increased therapeutic efficacy [132]. Here, TNFRSF4 is linked to breast cancer.